Welcome to the e-CCO Library!

P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y.S. Jung Prof. Dr.1, M. Han2, S. Park3, J.H. Cheon4

Created: Thursday, 30 January 2020, 10:12 AM
P405: 5-ASA prescription trends over time in inflammatory bowel disease 1996 to 2015–A UK population-based study
Year: 2018
Source: ECCO '18 Vienna
Authors:

V. Jairath1,2*, S. Hokkanen3, L. Guizzetti2, N. Boxall3, S. Campbell-Hill4, H. Patel4

Created: Thursday, 21 February 2019, 9:14 AM
P405: Development and validation of a rapid immunoassay for monitoring of ustekinumab concentrations in Inflammatory Bowel Disease patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Thomas, D.(1);Compernolle, G.(1);Guedelha Sabino, J.P.(2,3);Ferrante, M.(2,3);Vermeire, S.(2,3);Declerck, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P405: Infliximab trough level measured during treatment induction may be predictive of the loss of response to Infliximab during treatment maintenance in inflammatory bowel disease patients: a longitudinal observational retrospective study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

C. Liefferinckx*1, C. Minsart2, A. Cremer1, L. Amininejad1, J.-F. Toubeau3, E. Quertinmont2, J. Deviere1, A. Van Gossum1, D. Franchimont1

Created: Friday, 22 February 2019, 9:49 AM
P405: Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Panaccione, R.(1)*;Danese, S.(2);Wolf, D.C.(3);Canavan, J.B.(4);Jain, A.(4);Wu, H.(4);Petersen, A.(4);Charles, L.(4);Afzali, A.(5);Abreu, M.T.(6);
Created: Friday, 14 July 2023, 11:05 AM
P405: Primary non-response and loss-of-response to first-line biological therapies are more common in patients with Ulcerative Colitis than Crohn’s Disease – preliminary results from the Danish IBD Biobank Project
Year: 2022
Source: ECCO'22
Authors: Zhao, M.(1);Larsen, L.(2);Dige, A.(3);Hvas, C.L.(3);Poulsen, A.(4);Christiansen, D.(4);Attauabi, M.(1,5);Lo, B.(1);Wewer, M.(1,6);Ovesen, P.D.(6);Petersen, A.M.(1,7);Bendtsen, F.(1);Seidelin, J.B.(5);Burisch, J.(1,4);
Created: Friday, 11 February 2022, 3:52 PM
P405: Sustainability of biologic therapies is less in UC than CD patients independent of prior biologic experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. Doherty*1, M. Buckley1, G. Cullen1, D. Keegan1, K. Byrne1, G. Horgan1, H. Mulcahy1, J. Sheridan1, G. A. Doherty1,2

Created: Friday, 22 February 2019, 9:41 AM
P405: Toxicity of thiopurines in patients with inflammatory bowel disease: inventory and predictive factors
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Labidi A., Serghini M., Ben Mustapha N., Fekih M., Boubaker J., Filali A.

Created: Wednesday, 20 February 2019, 10:36 AM
P406 Adherence, acceptability and serum trough concentration of adalimumab autoinjector in quiescent patients with inflammatory bowel diseases
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Kato, N. Yamaga, A. Ishibashi, K. Kani, S. Nagoshi

Created: Thursday, 30 January 2020, 10:12 AM
P406: A retrospective analysis of the efficacy of vedolizumab on extra-intestinal manifestations in patients with inflammatory bowel disease across five European countries
Year: 2021
Source: ECCO'21 Virtual
Authors: Kopylov, U.(1);Burisch , J.(2); Ben-Horin , S.(1);Braegger, F.(3);Fernández-Nistal , A.(4);Lara, N.(5);Vavricka , S.(6,7);
Created: Wednesday, 2 June 2021, 4:12 PM
P406: AlphaE+ cells have increased expression of inflammatory markers and are correlated in the ileum and colon
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Ichikawa1, J. Eastham-Anderson1, A. Scherl1, J. Hackney1, L. Orozco1, W. Faubian2, J. Mansfield3, 4, J. Kirby3, C. Lamb3, 5, M. Keir*1

Created: Friday, 22 February 2019, 9:49 AM
P406: Clinical correlations of infliximab trough levels and antibodies to infliximab in Korean patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Oh E.H.*1, Ko D.-H.2, Seo H.3, Chang K.3, Kim G.-U.3, Song E.M.3, Seo M.3, Lee H.-S.4, Hwang S.W.3,5, Yang D.-H.3, Ye B.D.3,5, Byeon J.-S.3, Myung S.-J.3, Yang S.-K.3,5, Park S.H.3,5

Created: Wednesday, 20 February 2019, 10:36 AM
P406: Disease clearance in patients with ulcerative colitis treated with aminosalicylates
Year: 2022
Source: ECCO'22
Authors: Nascimento, C.(1);Revés, J.(1);Roque Ramos, L.(1);Carolina, P.(1);Fidalgo, C.(1);Glória, L.(1);Torres, J.(1);
Created: Friday, 11 February 2022, 3:52 PM
P406: General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. Danese*1, B. E. Sands2, R. W. Leong3,4, H. Zhang5, J. Johanns5, P. Szapary5, C. Marano5, C. Han6

Created: Friday, 22 February 2019, 9:41 AM
P406: Malnutrition during hospitalisation for acute severe IBD is associated with increased risk of relapse
Year: 2018
Source: ECCO '18 Vienna
Authors:

K. Kulmala1*, J. Björk2, S. Andersson3, A.-S. Backman1,2, C.R.H. Hedin2, F. Bresso2

Created: Thursday, 21 February 2019, 9:14 AM
P406: Observational study of the effectiveness of vedolizumab on treatment outcomes and health-related quality of life in biologic-naïve patients with Inflammatory Bowel Diseases in Greece – the TROVE study - Interim Analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chatzinikolaou-, M.L.(1)*;Kifnidi, C.(2);Kokkotis, G.(1);Gatopoulou, A.(3);Michopoulos, S.(4);Soufleris, K.(5);Poulopoulos, G.(6);Theodoropoulou, A.(7);Mantzaris, G.(8);Ntelis, V.(9);Papatheodoridis, G.(10);Tzouvala, M.(11);Koutroubakis, I.E.(12);Theocharis, G.(13);Kourikou, A.(14);Christodoulou, D.(15);Grammatopoulos, A.(16);Michalopoulos, G.(17);Georgopoulos, S.(18);Akriviadis, E.(19);Vradelis, S.(20);Gkagkari, V.(4);Zampeli, E.(4);Fasoulas, K.(5);Charalampidis, M.(6);Velegraki, M.(7);Karampekos, G.(8);Viazis, N.(8);Andrianakou , G.(9);Karatzas, P.(10);Tribonias, G.(11);Zacharopoulou, E.(11);Orfanoudaki, E.(12);Tsellou, E.(2);Psyrilos, A.(2);Roussou, D.(2);Bamias, G.(1);
Created: Friday, 14 July 2023, 11:05 AM
P407 Is the rapid infliximab infusion a safe and cost-saving strategy in paediatric inflammatory bowel disease?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

G. Pujol Muncunill1, J. Martínez-Osorio1, F. Bossacoma-Busquets2, L. Álvarez-Carnero1, J. Arrojo-Juárez2, V. Vila-Miravet1, F.J. Martin De Carpi1

Created: Thursday, 30 January 2020, 10:12 AM
P407: A Phase IB/IIA study of remestemcel-L, an allogeneic bone marrow derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: An interim analysis
Year: 2022
Source: ECCO'22
Authors: Lightner, A.(1);Dadgar, N.(2);Fulmer, C.(3);Ream, J.(4);Nachand, D.(4);Steele, S.(2);
Created: Friday, 11 February 2022, 3:52 PM
P407: Clinical manifestations of thiopurine S-methyltransferase variants in Korean paediatric patients with inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Kim*

Created: Friday, 22 February 2019, 9:49 AM
P407: Efficacy and safety of etrasimod in subjects with moderately to severely active isolated proctitis: a subgroup analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1,2)*;Dubinsky, M.C.(3);Sands, B.E.(4);Panés, J.(5);Schreiber, S.(6);Reinisch, W.(7);Feagan, B.G.(8);Danese, S.(9);Yarur, A.(10);D'Haens, G.(11);Goetsch, M.(12);Wosik, K.(13);Wu, J.(14);Modesto, I.(15);McDonnell, A.(16);Bartolome, L.(17);Rabbat, C.J.(18);Vermeire, S.(19);
Created: Friday, 14 July 2023, 11:05 AM